Controllare l’avvenuta comprensione delle informazioni

Spesso i pazienti pensano di aver compreso le informazioni rilevanti e si mostrano soddisfatti delle informazioni ricevute, anche quando la loro comprensione è insufficiente.

Per questo il medico sperimentatore dovrebbe controllare che il paziente abbia effettivamente compreso le informazioni ricevute. Da una parte il paziente andrebbe incoraggiato a porre domande. Inoltre, per verificare il suo livello di comprensione il medico può fare alcune domande di verifica. Chiedere al paziente: “Ha capito?” non ha molto senso: il paziente normalmente risponderà di sì. Il medico sperimentatore dovrà piuttosto chiedere al paziente di riformulare con parole proprie gli obiettivi e le procedure del trial, e se il paziente dimostra una comprensione inaccurata spiegare il trial di nuovo.

Esempi di domande sono:

1) mi dica con le parole sue di cosa tratta questo studio; 2) mi dica cosa pensa che le capiterà in questo studio;

3) cosa si aspetta di guadagnare prendendo parte in questo studio? Quali rischi potrebbe correre partecipando questo studio? Quali sono le alternative?

BIBLIOGRAFIA

1. Grady C. Clinical trial. In: The Hastings Center (Ed.). The Hastings Center Bioethics Briefing Book. New York: Hastings Center; 2008. pp. 21-24.

2. Nuremberg Military Tribunals. The Nuremberg Code. Trial of war criminals before the Nuremberg

Military Tribunals under Control Council Law n. 10. Nuremberg, October 1946 - April 1949.

Washington, DC: Government Printing Office; 1949-1953. Volume 2. p. 181-2.

3. World Medical Association. Declaration of Helsinki. Ethical Principles for Medical Research

Involving Human Subjects. Current version Seoul, October 2008. Disponibile all’indirizzo:

www.wma.net/e/policy/b3.htm; ultima consultazione 30/9/2009.

4. The National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. The Belmont Report: Ethical Principles and Guidelines for the Protection of Human

Subjects of Research. Washington, DC: US. Office for Protection from Research Risks (OPRR),

National Institutes of Health (NIH), Public Health Service (PHS), Human Health Service (HHS); 1979.

5. Jonsen AR, Veatch RM, LeRoy W. Source book in bioethics. A documentary history. Washington DC: Georgetown University Press; 1998.

6. Lock S, Wells F, Farthing MJG, Blunt J (Ed). Fraud and misconduct in biomedical research. 3rd ed. (1st ed: 1993) London, England: BMJ books. 2001.

7. Emanuel EJ, Wendler D, Grady C. What makes clinical research ethical? JAMA 2000;283(20):2701-11.

8. Agrawal M, Emanuel EJ. Ethics of phase I oncology studies: reexamining the arguments and data.

JAMA 2003;290:1075-82.

9. Von Hoff DD, Turner J. Response rates, duration of response and dose response effects in phase I studies of antineoplastics. Invest New Drugs 1991;9(1):115-22.

10. Roberts TG Jr, Goulart BH, Squitieri L, Stallings SC, Halpern EF, Chabner BA, Gazelle GS, Finkelstein SN, Clark JW. Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials. JAMA 2004;292(17):2130-40.

11. Horstmann E, McCabe MS, Grochow L, Yamamoto S, Rubinstein L, Budd T, Shoemaker D, Emanuel EJ, Grady C. Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J

Med 2005 Mar 3;352(9):895-904.

12. Miller FG, Joffe F. Benefit in phase 1 oncology trials: therapeutic misconception or reasonable treatment option? Clin Trials 2008; 5; 617-23.

13. Van Luijn HE, Musschenga AW, Keus RB, Robinson WM, Aaronson NK. Assessment of the risk/benefit ratio of phase II cancer clinical trials by Institutional Review Board (IRB) members. Ann

Oncol 2002 Aug;13(8):1307-13.

14. Joffe S, Miller FG. Rethinking risk-benefit assessment for phase I cancer trial. J Clin Oncol 2006;24(19):2987-90.

15. Koyfman SA, McCabe MS, Emanuel EJ, Grady C. A consent form template for phase I oncology trial. IRB 2009; 31(4):1-8.

16. Gifford F. The conflict between randomized clinical trial and the therapeutic obligation. J Med Phil 1986;11(4):347-66.

17. Fried C. Medical experimentation: personal integrity and social policy. New York: American Elsevier;1974.

19. Freedman B. Placebo control trial and the logic of scientific purpose. IRB 1990;12(6):5. 20. Chard JA, Lilford RJ. The use of equipoise in clinical trial. Soc Sci Med 1998;47(7):891-8. 21. Miller FG, Brody H. A critique of clinical equipoise. Hastings Cent Rep 2003;33(3)19-28.

22. Hellman S, Hellman DS. Of mice but not men: problems of the randomized controlled trial. N Engl J

Med 1991;324(22):1585-9.

23. Miller FG, Joffe S. Bench to bedside: mapping the moral terrain. Hastings Cent Rep 2008;38(2):30-42.

24. American Federation of Clinical Oncologic Societies. Access to quality cancer care: consensus statement. J Clin Oncol 1998;16(4):1628-30.

25. Peppercorn JM, Weeks JC, Cook EF, Joffe S. Comparison of outcomes in cancer patients treated within and outside clinical trial: conceptual framework and structured review. Lancet 2004;363(9405):263-8.

26. Braunholtz DA, Edwards SJL, Lilford RJ. Are randomized clinical trial good for us (in the short term)? Evidence of a “trial effect”. J Clin Epidemiol 2001;54(3):217-24.

27. Appelbaum PS, Roth LH, Lidz CW, Benson P, Winslade W. False hopes and best data: consent to research and the therapeutic misconception. Hastings Cent Rep 1987;17(2):20-24.

28. Tunis SR, Stryer DB, Clancy CM. Practical clinical trial. Increasing the value of clinical research for decision making in clinical and health policy. JAMA 2003;290:1624-32.

29. Studi di non inferiorità e di equivalenza: limiti e ambiguità [editoriale]. Bif 2006;XIII(3):97-8. 30. Presidenza del Consiglio dei Ministri - Comitato Nazionale per la Bioetica. Problemi bioetici nella

sperimentazione clinica con disegno di non inferiorità. 24 aprile 2009. Disponibile all’indirizzo: www.governo.it/bioetica/testi/problemi_bioetici_24_aprile_2009.pdf (ultima consultazione 5/8/09). 31. Pocock SJ. The pros and cons of noninferiority trial. Fund Clin Pharmacol 2003;17(4):483-90. 32. Fueglistaler P, Adamina M, Guller U. Non-inferiority trial in surgical oncology. Ann Surg Oncol

2007;14(5):1532-9.

33. Splawinski J, Kuzniar J. Clinical trial: active control vs placebo-what is ethical? Sci Eng Ethics 2004; 10(1):73-9.

34. Garattini S, Bertele V, Li Bassi L. How can research ethics committees protect patients better? Br

Med J 2003;326(7400):1199-201.

35. Daugherty CK, Ratain MJ, Emanuel EJ, Farrell AT, Schilsky RL. Ethical, scientific, and regulatory perspectives regarding the use of placebos in cancer clinical trial. J Clin Oncol 2008;26(8):1371-8. 36. Emanuel EJ, Miller FG. The ethics of placebo-controlled trial. A middle ground. N Engl J Med

2001;345(12):915-9.

37. Temple R, Ellenberg S. Placebo-controlled trial and active-control trial in the evaluation of new treatments part 1: ethical and scientific issues. Ann Intern Med 2000;133(6):455-63.

38. Temple R, Ellenberg S. Placebo-controlled trial and active-control trial in the evaluation of new treatments part 2: practical issues and specific cases. Ann Intern Med 2000;133(6):464-70.

39. Cubeddu LX, Hoffmann IS, Fuenmayor NT, Finn AL. Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. N Engl J Med 1990;322(12):810-6. 40. Gandara DR, Harvey WH, Monaghan GG, Perez EA, Stokes C, Bryson JC, Finn AL, Hesketh PJ.

The delayed-emesis syndrome from cisplatin: Phase III evaluation of ondansetron versus placebo.

Semin Oncol 1992; 19(4 suppl 10):67-71.

41. Gralla RJ, Itri LM, Pisko SE, Squillante AE; Kelsen DP; Braun DW Jr; Bordin LA; Braun TJ; Young CW. Antiemetic efficacy of high dose metoclopramide: Randomized trial with placebo and

prochlorperazine in patients with chemotherapy induced nausea and vomiting. N Engl J Med 1981;305(16):905-9.

42. Beck TM, Ciociola AA, Jones SE, Harvey WH, Tchekmedyian NS, Chang A, Galvin D, Hart. NE. Efficacy of oral ondansetron in the prevention of emesis in outpatients receiving cyclophosphamide based chemotherapy. Ann Intern Med 1992;118(6):407-413.

43. Rothman KJ, Michels KB. The continuing unethical use of placebo controls. N Engl J Med 1994;331(6):394.

44. Helft PR, Daugherty CK. Are we taking without giving in return? the ethics of research-related

biopsies and the benefits of clinical trial participation. J Clin Oncol 2006;24(30):4793-5.

45. Freedman B, Weijer C, Glass KC. Placebo orthodoxy in clinical research. I. Empirical and methodological myths. J Law Med Ethics 1996; 24(3):243-51.

46. Freedman B, Glass KC, Weijer C. Placebo orthodoxy in clinical research. II. Ethical, legal, and regulatory myths. J Law Med Ethics 1996; 24(3):252-9.

47. Wolinski H. The battle of Helsinki. EMBO Reports 2006;7(7):670-2.

48. Stang A, Hense HW, Jockel KH, Turner EH, Tràmer MR. Is it always unethical to use a placebo in a clinical trial? Plos Med 2005;2(3)177-80.

49. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schünemann HJ, GRADE working group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. Br Med J 2008;336(7650):924-6.

50. Amdur RJ, Biddle CJ. An algorithm for evaluating the ethics of a placebo-controlled trial. Int J

Cancer 2001;96(5):261-9.

51. Council for International Organizations of Medical Sciences (CIOMS). International Ethical

Guidelines for Biomedical Research Involving Human Subjects. 2002; CIOMS: Geneva;

Switzerland.

52. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline Choice of Control Group

and Related Issues in Clinical Trials E10. ICH; 2000. Disponibile all’indirizzo:

http://www.ich.org/LOB/media/MEDIA486.pdf (ultima consultazione 30/9/2009).

53. Montori VM, Devereaux PJ, Adhikari NK, Burns KE, Eggert CH, et al. Randomized trial stopped early for benefit: a systematic review . JAMA 2005;294(17):2203-09.

54. Moher D, Schulz KF, Altman DG, for he Consort Group. The Consort statement: revised recommendations for improving the quality of reports of parallel-group randomised trial. Lancet 2001;357(9623):1191-4.

55. Trotta F, Apolone G, Garattini S, Tafuri G. Stopping a trial early in oncology: for patients or for industry? Ann Oncol 2008;19(7):1347-53.

56. Cannistra SA. The ethics of early stopping rules: who is protecting whom? J Clin Oncol 2004;22(9):1542-5

57. McCutchan JA. Data and safety monitoring. In: Bankert EA, Amdur RJ. (Ed.). Institutional Review

Board. Management and function. Sudbury, MA: Jones and Bartlett Publishers; 2009. p. 262-4.

58. Glannon W. Phase I oncology trial: why the therapeutic misconception will not go away. J Med

Ethics 2006;32(5):252-5.

59. Meropol NJ, Weinfurt KP, Burnett CB, Balshem A, Benson AB, Castel L, et al. Perceptions of patients and physicians regarding phase I cancer clinical trial: implications for physician-patient communication. J Clin Oncol 2003;21(13):2589-96.

60. Applebaum PS, Roth LH, Lidz C. The therapeutic misconception: informed consent in psychiatric research. Int J Law Psychiatry 1982;5(3-4):319-29.

61. Henderson GE, Churchill LR, Davis AM, Easter MM, Grady C, Joffe S, et al. Clinical trial and medical care: defining the therapeutic misconception. Plos Med 2007;4(11):1735-8.

62. National Bioethics Advisory Commission. Ethical and policy issues in international research:

Clinical trial in developing countries. Washington, DC: NBAC; 2001. Disponibile all’indirizzo:

http://bioethics.georgetown.edu/nbac/clinical/execsum.html (ultima consultazione 30/9/2009). 63. Kimmelman J. The therapeutic misconception at 25:treatment, research and confusion. Hastings Cent

Rep 2007;37(6):36-42.

64. King NMP. Accident and desire: inadvertent germline effects in clinical research. Hastings Cent Rep 2003;33(2):23-30.

65. de Melo-Martìn I, Ho A. Beyond informed consent: the therapeutic misconception and trust. J Med

Ethics 2008;34(3):202-5.

66. Applebaum PS, Lidz CW, Grisso T. Therapeutic misconception in clinical research: frequency and risk factors. IRB 2004;26(2):1-8.

67. Agrawal M, Grady C, Fairclough DL, Meropol NJ, Maynard K, Emanuel EJ. Patients’ decision-making process regarding participation in phase I oncology research. J Clin Oncol 2006;24(27):4479-84.

68. Daugherty CK, Siegler M, Ratain MJ, Zimmer G. Learning from our patients: one participant’s impact on clinical trial research and informed consent. Ann Intern Med 1997;126(11):892-7.

69. Joffe S, Cook EF, Cleary PD, Clark JW, Weeks JC. Quality of informed consent in cancer clinical trial: a cross sectional survey. Lancet 2001;358(9295):1772-7.

70. Coyne CA, Xu R, Raich P, Plomer K, Dignan M, Wenzel LB, et al. Randomized, controlled trial of an easy-to-read informed consent statement for clinical trial participation: a study of the Eastern Cooperative Oncology Group. J Clin Oncol 2003;21(5):836–42.

71. National Cancer Institute. Simplification of Informed Consent Documents. Recommendations.

Rockville, MD: NCI; 2009. Disponibile all’indirizzo: http://www.cancer.gov/clinicaltrials/understanding/simplification-of-informed-consent-docs/page2

(ultima consultazione 30/9/2009).

72. Associazione Italiana di Oncologia Medica. Modello di Informazione/Consenso Informato AIOM. Disponibile all’indirizzo: www.aiom.it/Attivit%E0+Scientifica/Documenti+AIOM/1,22,1 (ultima consultazione 5/8/09).

73. Jefford M, Moore R. Improvement of informed consent and the quality of consent documents. Lancet

Oncol 2008;9(5):485–93.

74. Horng S, Emanuel E, Wilfond B, Rackoff J, Martz K, Grady C. Descriptions of benefits and risks in consent forms for phase I oncology trial. New Engl J Med 2002;347(6):2134-40.

75. Brown RF, Butow PN, Butt DG, Moore AR, Tattersall MHN. Developing ethical strategies to assist oncologists in seeking informed consent to cancer clinical trial. Soc Sci Med 2004;58(2):379-90. 76. Gattellari M, Butow PN, Tattersall MHN. Shared decisions in cancer care. Soc Sci Med

2001;52(12):1865-78.

77. Jenkins VA, Fallowfield LJ, Souhami A, Sawtell M. How do doctors explain randomised clinical trial to their patients? Eur J Cancer 1999;35(8):1187–93.

78. Kodish E, Eder M, Noll RB, Ruccione K, Lange b, Angiolillo A, Pentz R, Zyzanski S, Siminoff LA, Drotar D. Communication of randomization in childhood leukemia trial. JAMA 2004; 291(4): 470-75.

La riproduzione parziale o totale dei Rapporti e Congressi ISTISAN deve essere preventivamente autorizzata.

Le richieste possono essere inviate a: pubblicazioni@iss.it.

Stampato da Tipografia Facciotti srl Vicolo Pian Due Torri 74, 00146 Roma